Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue-type plasminogen activator.

H R Lijnen, D Collen

    Annales De Biologie Clinique
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Tissue-type plasminogen activator (t-PA) efficiently activates plasminogen to plasmin, especially on fibrin clots. This targeted action makes t-PA a specific and effective thrombolytic agent with minimal systemic effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impaired fibrinolysis and the risk for coronary heart disease.

    Circulation·1996
    Same author

    Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

    European journal of biochemistry·1996
    Same author

    Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.

    Thrombosis and haemostasis·1996
    Same author

    Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

    Circulation·1996
    Same author

    A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

    Thrombosis and haemostasis·1996
    Same author

    Role of tissue factor in embryonic blood vessel development.

    Nature·1996
    Same journal

    [The role of the heart-on-a-chip to drug evaluation].

    Annales de biologie clinique·2026
    Same journal

    A morphology-driven proof-of-concept study linking interphase nuclear abnormalities to dicentric-mediated genomic instability.

    Annales de biologie clinique·2026
    Same journal

    Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

    Annales de biologie clinique·2026
    Same journal

    Small-cell secondary plasma cell leukemia mimicking low-grade B-cell lymphoma.

    Annales de biologie clinique·2026
    Same journal

    [Multiple myeloma and analytical discrepancy in serum free light chain assay: a case report].

    Annales de biologie clinique·2026
    Same journal

    [Summary of the 34th National Conference of the National College of Hospital Biochemistry].

    Annales de biologie clinique·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Pharmacology

    Background:

    • Tissue-type plasminogen activator (t-PA) is a key serine protease in fibrinolysis.
    • Its enzymatic activity involves cleaving plasminogen to form plasmin.
    • Fibrin significantly influences the kinetics of plasminogen activation by t-PA.

    Purpose of the Study:

    • To investigate the kinetic properties of t-PA-mediated plasminogen activation.
    • To elucidate the role of fibrin in enhancing t-PA's activity.
    • To evaluate the thrombolytic potential and specificity of t-PA.

    Main Methods:

    • Kinetic analysis using Michaelis-Menten kinetics.
    • In vitro studies assessing plasminogen activation in the presence and absence of fibrin.

    Related Experiment Videos

  • In vivo studies in animal models and clinical investigations in patients.

    • Main Results:

    • t-PA activation of plasminogen follows Michaelis-Menten kinetics.
    • Fibrin dramatically enhances t-PA's activation rate, indicated by a lower Michaelis constant (0.16 microM vs. 65 microM).
    • Plasmin generated on fibrin is protected from alpha 2-antiplasmin, and t-PA demonstrates specific thrombolysis with limited systemic fibrinolytic activation.

    Conclusions:

    • t-PA exhibits highly efficient and specific plasminogen activation on fibrin clots.
    • The fibrin-mediated enhancement of t-PA activity explains its targeted thrombolytic action in vivo.
    • t-PA is a potent thrombolytic agent with a favorable safety profile due to localized fibrinolysis.